cdio stock guide

cdio stock refers to Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a U.S. precision cardiovascular diagnostics company using integrated genetic‑epigenetic AI tests. This guide explains the comp...

2024-07-06 10:08:00

By Blockchain Nomad

Article rating

4.6

115 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cardio Diagnostics Holdings, Inc. (CDIO)

Lead summary

cdio stock refers to the NASDAQ‑listed common shares of Cardio Diagnostics Holdings, Inc., a U.S. company focused on precision cardiovascular diagnostics that combine genetic and epigenetic biomarkers and AI analytics. The company’s primary clinical offerings include laboratory tests marketed under PrecisionCHD and Epi+Gen CHD, along with reporting platforms such as HeartRisk and CDIO.AI that translate assay results into actionable clinical intelligence. cdio stock trades on Nasdaq under the ticker CDIO and is categorized as an early‑stage, small‑cap healthcare technology company.

This article provides a comprehensive, beginner‑friendly overview of the company, technology, products, regulatory and reimbursement context, recent corporate actions (including the May 2025 reverse split), financials, stock performance, risks, and where to find official investor materials. It is informational only and not investment advice.

Company overview

Cardio Diagnostics Holdings, Inc. positions itself at the intersection of molecular biomarker science and clinical decision support. The company’s stated mission is to improve cardiovascular disease detection and risk stratification by integrating genetic (DNA sequence variants) and epigenetic (DNA methylation) markers with advanced machine learning models — an approach they call the Integrated Genetic‑Epigenetic Engine.

The target markets for Cardio Diagnostics include primary care, cardiology clinics, preventive health programs, and provider networks that screen or risk‑stratify patients for coronary heart disease (CHD) and related cardiovascular conditions. Tests use peripheral blood samples and aim to provide clinicians with a higher‑resolution view of patient risk than traditional clinical risk calculators alone.

As of the reporting in multiple financial and news outlets, cdio stock represents the publicly traded equity for investors tracking the company’s commercialization progress and clinical validation milestones.

History

Founding and early milestones

Cardio Diagnostics was founded to commercialize multi‑omic biomarker panels for cardiovascular disease. Early work focused on biomarker discovery, assay development, and pilot clinical validation, moving from research‑use assays toward CLIA‑run clinical laboratory services. The company invested in building a regulatory, laboratory and data analytics infrastructure to support clinical testing and provider reporting.

Recent corporate actions

As of May 2025, Cardio Diagnostics announced and executed a 1‑for‑30 reverse stock split as part of efforts to regain Nasdaq minimum bid price compliance and restructure the company’s equity base. As of that corporate action, news outlets reported the split and subsequent adjustments to share counts and price per share. Several sources also noted past trading halts and heightened volatility tied to low share price levels and corporate restructuring events. (As of May 2025, these corporate actions were reported across financial news services.)

Products and services

PrecisionCHD and Epi+Gen CHD

PrecisionCHD: A clinical diagnostic assay combining selected genetic variants and a targeted epigenetic methylation panel to assess an individual’s risk of coronary heart disease. The test is designed for venous blood samples and produces a risk score intended to supplement clinical judgment in primary care or cardiology settings.
Epi+Gen CHD: A companion or alternative assay that emphasizes epigenetic markers (methylation signatures) alongside genetic data to identify active disease processes or risk states not captured by genetics alone. Epi+Gen CHD aims to detect dynamic disease signals that might reflect environmental exposure, lifestyle, or recent pathophysiology.

Actionable Clinical Intelligence / HeartRisk / CDIO.AI

Cardio Diagnostics provides reporting and analytics platforms that convert raw assay outputs into clinician‑friendly summaries. HeartRisk and CDIO.AI are branded solutions that integrate laboratory results with algorithmic risk models, clinical decision support, and suggested next steps (e.g., further testing, referrals, preventive therapies). These platforms are intended to improve test utility by highlighting actionable findings and supporting documentation for providers.

Technology and research

Integrated genetic‑epigenetic approach

The company’s core technical premise is that combining static genetic variants (germline SNPs and known risk alleles) with dynamic epigenetic markers (DNA methylation at specific CpG sites) yields higher discriminative performance for cardiovascular disease risk than either approach alone. Methylation panels can reflect prior exposures and emerging pathophysiology; when coupled with machine learning, they can be used to produce calibrated risk scores.

AI and algorithm engine

Cardio Diagnostics describes its analytics as an Integrated Genetic‑Epigenetic Engine leveraging supervised machine‑learning models trained on clinical cohorts. The engine ingests multi‑omic signals plus clinical covariates to produce risk probabilities and classification outputs for coronary heart disease presence or near‑term events. The company emphasizes explainability in reports so clinicians can review contributing biomarkers and thresholds.

Clinical validations and conference presentations

Cardio Diagnostics has presented validation and performance data at clinical conferences and in press releases. As reported by financial media and company materials, the company has participated in sessions at major cardiology meetings (for example, ACC‑related presentations noted in company releases). Clinical validation activities typically include sensitivity, specificity, area under the ROC curve (AUC) metrics relative to comparator strategies, though independent peer‑reviewed publications may be limited or in development.

Regulatory and reimbursement

Regulatory status

Cardio Diagnostics operates clinical testing under CLIA‑certified laboratory conditions in the U.S., which allows the company to offer laboratory‑developed tests (LDTs) to clinicians. Distinctions between research‑use only (RUO) assays and CLIA clinical offerings are important; company materials often specify which products are for clinical use. As typical in U.S. molecular diagnostics, broader FDA clearance or approval may not be required for CLIA LDT operations, but FDA interactions and evolving regulatory guidance can affect market access.

Reimbursement developments

As of recent company announcements and financial reporting, Cardio Diagnostics has pursued reimbursement pathways including private payer discussions and engagements with Medicare pricing processes. Some press reports highlighted CMS preliminary or final pricing steps for related molecular diagnostics in cardiovascular disease that could affect commercial uptake. As of the time of those reports, reimbursement coverage remained a key commercial milestone — successful payer coverage can materially influence adoption and revenue. (As of May 2025, news sources reported CMS pricing determination activity relevant to novel diagnostics.)

Implications for commercialization

Without broad, stable reimbursement, adoption may rely on point‑of‑care purchasing, direct contracting with health systems, or out‑of‑pocket patient payments. Coverage decisions by Medicare and major commercial payers typically hinge on demonstrated clinical utility, guideline recognition, and cost‑effectiveness data.

Commercialization and partnerships

Provider networks and rollouts

Cardio Diagnostics has announced partnerships and provider trials intended to expand test availability in primary care and cardiology networks. These agreements commonly start as pilot implementations with selected clinics or telehealth partners to validate workflow integration and clinician acceptance.

Distribution channels and go‑to‑market strategy

The company’s go‑to‑market approach combines direct provider outreach, integration into electronic health record (EHR) order flows where possible, telehealth partnerships for sample collection and result communication, and lab‑to‑lab collaborations. Marketing emphasizes how PrecisionCHD and Epi+Gen CHD can fit into preventive cardiology pathways and help clinicians prioritize interventions.

Corporate governance and management

Headquarters and leadership

Cardio Diagnostics lists its corporate offices and laboratory operations in the U.S. The company is led by a management team with backgrounds in diagnostics, clinical research, and commercialization. Public filings and company releases name the chief executive officer, chief scientific officer, and other senior executives, along with board members who bring clinical and commercial experience.

Ownership and employees

As a small public company, Cardio Diagnostics shows a mix of insider ownership and institutional holdings. Employee headcount is modest compared with larger diagnostics companies, reflecting the company’s early commercialization stage and laboratory‑focused operations.

Financials

High‑level financial summary

As a small‑cap diagnostic company still in commercialization and scaling phases, Cardio Diagnostics has reported limited product revenue with net losses typical for early‑stage life sciences companies. Reported balance sheets have historically shown cash and cash equivalents that the company manages to fund laboratory operations, validation studies, and go‑to‑market activities.

Public reporting cadence

Investors can find up‑to‑date financial statements, Form 10‑Q and 10‑K filings, and current corporate disclosures through the company’s investor relations materials and SEC filings. Regular quarterly reporting outlines revenue, operating expenses, cash runway, and key milestones — monitoring these filings is essential to track commercialization progress.

Stock information and market performance

Listing details

cdio stock is listed on the Nasdaq exchange under the ticker CDIO. In May 2025 the company implemented a 1‑for‑30 reverse stock split to address Nasdaq minimum bid price requirements and consolidate the equity base.

Historical price performance and volatility

cdio stock has exhibited high volatility typical of small‑cap and early‑stage healthcare equities. Reverse splits and low float can amplify percentage moves; trading halts and thin volume have also contributed to sporadic price behavior. Investors tracking cdio stock should be aware of the effects of corporate actions (such as reverse splits) on per‑share pricing and on historical charts.

Corporate actions affecting the stock

The May 2025 1‑for‑30 reverse split significantly changed the numerical share count and per‑share price. Reverse splits reduce outstanding shares while increasing per‑share nominal price and can be used to satisfy listing rules but do not by themselves change company enterprise value. In addition to the reverse split, some trading halts and subsequent resumed trading events were reported by market data providers during periods of corporate announcements.

Risks and controversies

Business risks

Clinical adoption risk: New diagnostics must demonstrate clear clinical utility to change provider behavior and guideline recommendations.
Reimbursement risk: Payer coverage and pricing will materially affect revenue potential; uncertain or delayed coverage poses commercialization risk.
Concentration risk: Reliance on a small number of products or test portfolios increases vulnerability if performance or acceptance is limited.

Market / stock risks

Small‑cap and low‑float stocks such as cdio stock are often highly volatile and may experience wide intraday swings.
Reverse splits can signal previous price weakness and are sometimes associated with continued volatility.
Dilution risk: Early companies may raise capital through equity or convertible instruments, potentially diluting existing shareholders.

Regulatory and operational risks

Evolving regulatory guidance for laboratory‑developed tests can influence permissible workflows and market access.
Quality control and laboratory compliance are critical: any adverse lab inspection results or operational failures could disrupt testing services and damage reputation.

Investor relations

Accessing investor materials

Investors should use the company’s official investor relations page and SEC filings as primary sources for accurate, timely information. Quarterly and annual reports (Form 10‑Q, 10‑K), current reports (Form 8‑K), and press releases provide data on financials, corporate actions, and strategic initiatives.

Key investor metrics to monitor

Revenue growth and payer coverage developments.
Cash position and burn rate to assess runway and potential financing needs.
Clinical validation milestones and peer‑reviewed publications that support broader adoption.
Stock structure items such as shares outstanding (post‑reverse split), warrants, and convertible securities that affect dilution.

References

Yahoo Finance — Cardio Diagnostics Holdings, Inc. (CDIO) quote and company profile (referenced for market quote and trading metrics).
Reuters / Refinitiv — Company profile and corporate action reporting (referenced for reverse split and listing status).
Finviz — Quotation and news aggregation for CDIO.
Morningstar — CDIO quote and basic financial metrics.
Robinhood — CDIO stock data and user commentary.
CNBC — CDIO quote and related market commentary.
CNN Markets — CDIO market page and stock metrics.
StockTwits — CDIO symbol page and community sentiment.
StockTitan — News hub for CDIO updates.
StockAnalysis — Company and news summaries for CDIO.

As of May 2025, multiple outlets reported on the company’s 1‑for‑30 reverse split and listing compliance steps; readers should consult the sources above for dated press releases and market data.

External links

Official company website and investor relations page (CDIO corporate materials).
SEC EDGAR filings page for Cardio Diagnostics Holdings, Inc.
Major financial quote pages: Yahoo Finance, Morningstar, Finviz (for market snapshot and historical charts).

Further exploration and next steps

If you want to monitor cdio stock more closely, start by bookmarking the company’s investor relations page and subscribing to SEC filings alerts. For trade execution, consider using Bitget’s equities trading platform for transparent order routing and market data. If you use a Web3 wallet in tandem with financial tools, Bitget Wallet is the recommended wallet when accessing Bitget services.

Stay fact‑driven: confirm any market data against primary sources (SEC filings, official press releases, and exchange quote pages). For questions about how to view CDIO quotes on Bitget or to learn more about the company’s latest filings and conference presentations, check Bitget’s market tools and the company’s latest press releases.

Explore more: track clinical validation updates, payer coverage announcements, and the company’s quarterly results to understand how commercialization is progressing and how those developments may affect cdio stock liquidity and volatility.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.